Related Experiment Video
Updated: Aug 13, 2026
12:19
Antibody Profiling by Luciferase Immunoprecipitation Systems LIPS
Published on: October 7, 2009
27.8K
Extended Antiphospholipid Antibodies Screening in Systemic Lupus Erythematosus Patients
Summary
Antiphospholipid antibodies (APLAs), specifically IgG anti-beta-2 glycoprotein I (aβ2GPI), are significantly associated with secondary antiphospholipid syndrome (APS) in systemic lupus erythematosus (SLE) patients. Higher aβ2GPI titers increase the risk of developing APS in SLE.
Area of Science:
- Rheumatology
- Immunology
- Autoimmunity
Background:
- Antiphospholipid syndrome (APS) frequently co-occurs with systemic lupus erythematosus (SLE).
- The intricate pathogenesis linking APS and SLE necessitates further investigation into associated biomarkers.
- Understanding these associations can improve diagnostic and prognostic strategies for SLE patients.
Purpose of the Study:
- To investigate the association between antiphospholipid antibodies (APLAs) titers and the diagnosis of secondary APS in patients with SLE.
- To identify specific APLAs that serve as risk factors for secondary APS in SLE.
- To explore correlations between non-criteria APLAs and SLE disease markers.
Main Methods:
- Sixty-five SLE patients were classified based on APS diagnosis and APLAs status according to established criteria.
- An extended panel of IgM and IgG antiphospholipid antibodies was analyzed, including anticardiolipin (aCL), anti-P2 glycoprotein I (aβ2GPI), antiphosphatidylethanolamine (aPE), antiphosphatidylserine (aPS), and antiprothrombin (aPT).
- Statistical analyses, including Kruskal-Wallis test and logistic regression, were employed to determine significant associations and risk factors.
Main Results:
- Significantly higher titers of both IgM and IgG anti-P2 glycoprotein I (aβ2GPI) antibodies were observed in SLE patients with secondary APS compared to those without APS.
- Logistic regression identified IgG and IgM aβ2GPI as significant risk factors for secondary APS in SLE patients, with IgG aβ2GPI conferring a nearly 6-fold increased risk.
- Non-criteria APLAs (aPS, aPT, aPE) showed correlations with anti-DNA titers (IgG) and inverse association with complement C3 levels (IgM).
Conclusions:
- IgG anti-P2 glycoprotein I (aβ2GPI) antibodies are strongly associated with an increased risk of secondary APS in SLE patients.
- Non-criteria antiphospholipid antibodies do not appear to be directly associated with the diagnosis of APS in SLE patients.
- Observed correlations between non-criteria APLAs and SLE markers like anti-DNA and C3 levels warrant further investigation.
